Emisphere Technologies Inc (EMIS)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Emisphere Technologies Inc (EMIS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012297
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Emisphere Technologies Inc (Emisphere) is a specialty pharmaceutical and drug delivery company. The company in partnership with global pharmaceutical companies develops novel oral formulations of existing injectable bio-pharmaceutical products, besides new chemical entities, using its Eligen technology. Its lead product Eligen B12, is the first and only once-daily oral prescription medical food approved in the US for treatment of vitamin b12 deficiency. The product is sold through a range of distributors, sellers, and other sources. Emisphere also uses its proprietary Eligen technology to produce novel oral formulations of therapeutic agents. The company’s product pipeline includes prescription drugs and medical food products that are being developed in partnership or internally. Emisphere is headquartered in Roseland, New Jersey, the US.

Emisphere Technologies Inc (EMIS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Emisphere Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Emisphere Technologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Emisphere Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Emisphere Technologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Emisphere Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Emisphere Technologies Inc, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Novo Nordisk Enters into Licensing Agreement with Emisphere 10
Novo Nordisk Amends Licensing Agreement with Emisphere 12
Emisphere Technologies Amends Licensing Agreement With Novo Nordisk For GLP-1 Receptor 13
Equity Offering 14
Emisphere Technologies Completes Private Placement Of Units For US$3.75 Million 14
Emisphere Technologies Issues Units To MHR In Private Placement For US$3.75 Million 15
Emisphere Technologies Inc – Key Competitors 16
Emisphere Technologies Inc – Key Employees 17
Emisphere Technologies Inc – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Financial Announcements 19
May 12, 2017: Emisphere Reports First Quarter 2017 Financial Results 19
Mar 29, 2017: Emisphere Reports Fourth Quarter and Full Year 2016 Financial Results 20
Nov 14, 2016: Emisphere Reports Third Quarter 2016 Financial Results 23
Aug 15, 2016: Emisphere Reports Second Quarter 2016 Financial Results 26
May 16, 2016: Emisphere Reports First Quarter 2016 Financial Results 29
Mar 29, 2016: Emisphere Reports Fourth Quarter and Full Year 2015 Financial Results 31
Other Significant Developments 34
Dec 09, 2016: Emisphere Restructures Debt Agreements, Providing Greater Stability for Business Growth and Expansion 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Emisphere Technologies Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Emisphere Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Emisphere Technologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Emisphere Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Emisphere Technologies Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Emisphere Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Novo Nordisk Enters into Licensing Agreement with Emisphere 10
Novo Nordisk Amends Licensing Agreement with Emisphere 12
Emisphere Technologies Amends Licensing Agreement With Novo Nordisk For GLP-1 Receptor 13
Emisphere Technologies Completes Private Placement Of Units For US$3.75 Million 14
Emisphere Technologies Issues Units To MHR In Private Placement For US$3.75 Million 15
Emisphere Technologies Inc, Key Competitors 16
Emisphere Technologies Inc, Key Employees 17

★海外企業調査レポート[Emisphere Technologies Inc (EMIS)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Lisega SE:企業の戦略的SWOT分析
    Lisega SE - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Alkermes Plc (ALKS):企業の財務・戦略的SWOT分析
    Alkermes Plc (ALKS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Doosan Fuel Cell America Inc:電力:M&Aディール及び事業提携情報
    Summary Doosan Fuel Cell America Inc (Doosan Fuel Cell), formerly Quantum Leap Technology Inc, a subsidiary of Doosan Corp, is a energy solution provider that manufactures and markets clean energy solutions. The company provides installation, remote monitoring and control, equipment service, financi …
  • Genisphere LLC-製薬・医療分野:企業M&A・提携分析
    Summary Genisphere LLC (Genisphere) is a nanotechnology company which provides DNA-based targeted drug delivery solutions. The company utilizes its proprietary 3DNA platform which enables the application in gene delivery, biologics, small molecules, and RNAi therapuetics. It develops pipeline produc …
  • IDG Communications Inc:企業の戦略的SWOT分析
    IDG Communications Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Chinook Energy Inc (CKE):石油・ガス:M&Aディール及び事業提携情報
    Summary Chinook Energy Inc (Chinook) is an oil and gas company that offers exploration, development and production of oil and gas properties in Western Canada. The company explores and develops crude oil, natural gas liquids and natural gas. It develops inventory from the BBT Concession, exploration …
  • Dogus Otomotiv Servis ve Ticaret AS:戦略・SWOT・企業財務分析
    Dogus Otomotiv Servis ve Ticaret AS - Strategy, SWOT and Corporate Finance Report Summary Dogus Otomotiv Servis ve Ticaret AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Norwegian Cruise Line Holdings Ltd. (NCLH):企業の財務・戦略的SWOT分析
    Norwegian Cruise Line Holdings Ltd. (NCLH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Co-Diagnostics Inc:企業の製品パイプライン分析2018
    Summary Co-Diagnostics Inc (Co-Diagnostics) is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The company’s products include HCV RNA real-time PCR kit, HIV RNA real-time PCR kit, malaria DNA real-time PCR kit, and TB complex DNA kit …
  • Tesla Energy Operations Inc:企業の戦略的SWOT分析
    Tesla Energy Operations Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Harbin Gloria Pharmaceuticals Co Ltd (002437):企業の財務・戦略的SWOT分析
    Summary Harbin Gloria Pharmaceuticals Co Ltd (Harbin Gloria) is a pharmaceutical company that produces and markets nutritional drugs. The company’s products include pharmaceutical drugs for treating nutrition disorders, cancer, cardiovascular diseases, anti-tumor medication, respiratory medication, …
  • Turk Hava Yollari Anonim Ortakligi:企業の戦略・SWOT・財務情報
    Turk Hava Yollari Anonim Ortakligi - Strategy, SWOT and Corporate Finance Report Summary Turk Hava Yollari Anonim Ortakligi - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Mitochon Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Mitochon Pharmaceuticals Inc (Mitochon Pharma) is a biotech company that develops drugs for neurodegenerative and neuromuscular diseases. The company’s pipeline products comprise mitochondrial modulators such as MP-101, MP-201 and MP-301. It targets diseases such as batten disease, stroke, h …
  • Orthosera GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Orthosera GmbH (OrthoSera), formerly Lacerta Technologies GmbH is a regenerative medicine company that develops blood serum for human diseases. The company offers Albumin, a bone protein used in treatment of patients suffering from bone loss. It develops technologies for identification of ne …
  • NeoTract Inc:医療機器:M&Aディール及び事業提携情報
    Summary NeoTract Inc (NeoTract) is a medical device company that designs and develops minimally invasive devices for use in the field of urology. The company’s urolift system is designed to treat lower urinary tract symptoms caused by benign prostatic hyperplasia. It partners with its customers to i …
  • OncoMed Pharmaceuticals Inc (OMED):企業の財務・戦略的SWOT分析
    Summary OncoMed Pharmaceuticals Inc (OncoMed) is a clinical-stage biopharmaceutical company focused on discovery and development of novel immuno-oncology (IO) therapeutics for the treatment of cancers. Its pipeline product candidates include navicixizumab, rosmantuzumab, Gitrl-FC Trimer, and anti-TI …
  • Symantec Corporation:企業の戦略・SWOT・財務分析
    Symantec Corporation - Strategy, SWOT and Corporate Finance Report Summary Symantec Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Spine Injury Solutions Inc (SPIN):企業の財務・戦略的SWOT分析
    Summary Spine Injury Solutions Inc (SPIN), formerly Spine Pain Management Inc is a medical service provider that provides medical technology and healthcare management solutions for liability spine injuries. The company provides services such as clinical management, and billing and collection of medi …
  • UPM-Kymmene Corp:企業の戦略・SWOT・財務分析
    UPM-Kymmene Corp - Strategy, SWOT and Corporate Finance Report Summary UPM-Kymmene Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Carriage Services Inc (CSV):企業の財務・戦略的SWOT分析
    Summary Carriage Services Inc (Carriage Services) is a provider of professional funeral and cemetery products and services. The company’s operations include funeral homes operation, cemeteries operations, cemetery locations and crematoria, and combined funeral home. It provides funeral home operatio …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆